Zydus Lifesciences board meeting on Nov 4 to consider Q2 results

Revenue growth above 20%EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1123.00

prior close

₹1116.90

announcement price

In-mkt

timing

Nifty 100market-1.0%+0.2% vs market

Pharmaceuticals peers, median of 172sector-1.6%+0.8% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty 100 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.1

15m

+0.2

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-1.0+0.2-1.6+0.8

Next day

-0.5-1.5+1.0-3.5+3.0

+1.1-2.1+3.1-3.8+4.9

+0.6-2.8+3.3-5.3+5.9

+2.8-2.1+4.9-4.1+7.0

+4.4-1.8+6.3-2.4+6.8

+5.8-1.0+6.7-1.3+7.1

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has informed exchanges that its Board of Directors will meet on November 4, 2026 to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The trading window for directors and designated persons will remain closed until November 6 and reopen on November 9.

Likely market impact

Routine pre-results announcement. Actual Q2 FY27 numbers will be disclosed after the board meeting on November 4.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹7,910 Cr	₹6,123 Cr	+29.2%
Operating profit	₹1,103 Cr	₹1,613 Cr	−31.6%
Profit after tax	₹927.7 Cr	₹1,239 Cr	−25.1%
EBITDA margin	24.0%	32.4%	−8.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.